RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
RedHill Biopharma Ltd. revenue by segment
By business segment
| Operating income | Q2 22 | Q2 21 | Q2 20 | Q2 19 | Q2 18 | Q2 17 | YoY |
|---|---|---|---|---|---|---|---|
| Commercial Operations | – | -$10.08M | -$8.03M | -$3.60M | -$2.00M | -$3.35M | – |
| Research and Development | – | -$14.81M | -$4.47M | -$8.78M | -$7.56M | -$10.19M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of RedHill Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.